Linfoma de Hodkin en Chile: Experiencia de 15 años del Programa Nacional de Cáncer del Adulto

Median age was 37 years (15-84). Nodularsclerosis and mixed cellularity were equally expressed. Advanced stages (III & IV) were present atdiagnosis in 61% of cases. Age over 40 was an adverse prognostic factor (p <0.001). The rate of PFS at5 and 10 years for early stages was 73% and 66% with RT, 80% and 74% with C-MOPP+RT, 73% and71% with C-MOPP/ABV, 59% and 59% with NOVP+RT, and 81% with ABVD+RT, at 5 years, beingsignificantly lower for NOVP (p =0.02). The rate of OS at 5 and 10 years for advanced stages was 82%and 70% with RT, 82% and 76% with C-MOPP+RT, 82% and 80% with C-MOPP/ABV, 68% and 60%with NOVP, and 85% with ABVD at 5 years, also significantly lower for NOVP (p =0.04). For advancedstages, the rate of PFS at 5 and 10 years was 49% and 43% with C-MOPP, 69% and 62% with C-MOPP/ABVD or C-MOPP/ABV, and 71% at 5 years with ABVD, significantly lower for C-MOPP (p=0.01). The rate of OS at 5 and 10 years was 52% and 46% with C-MOPP, 70% and 63% with C-MOPP/ABVD or C-MOPP/ABV and 76% with ABVD at 5 years, significantly lower for C-MOPP (p=0.0002).